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MicroRNAs are small single-stranded RNA molecules consisting of approximately 22 nucleotides (nt), and have post-transcrip- 
tional regulatory functions. By gene chip screening, we previously showed that miR-142-3p was significantly upregulated in col-
orectal cancer tissue and was associated with clinicopathological features, compared with matched non-tumor tissue. In this study, 
we confirmed significant upregulation of miR-142-3p in 60 colorectal cancer samples and three colorectal cancer cell lines by 
quantitative real-time PCR (qRT-PCR). Using software and network resources, we predicted TCF7 as a target of miR-142-3p, 
which we confirmed with dual-luciferase assays. By RT-PCR and Western blot analysis, we found miR-142-3p negatively regu-
lates TCF7 expression post-transcriptionally. CCK8 assays and growth curves indicated that overexpression of miR-142-3p in 
SW480 colorectal cancer cells potently inhibited cell proliferation in vitro. The expression of TCF7 mRNA and protein was up-
regulated in both colorectal cancer tissues and colorectal cancer cell lines, closely correlating with its function as an oncogene in 
promoting tumor cell proliferation and inhibiting apoptosis. With TCF7 as a direct target, our results suggested that miR-142-3p 
may be involved in the regulation of cell proliferation in colorectal cancer. 
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Cancer is the third leading cause of death worldwide, after 
cardiovascular and infectious diseases. Colorectal cancer is 
the third most common cancer diagnosed, and is a cause of 
mortality in both men and women in the United States [1]. 
In the past few years, many methods such as colonoscopy, 
blood tests for tumor markers, ultrasound, magnetic reso-
nance imaging (MRI), computed tomography (CT or CAT) 
scanning, and positron emission tomography (PET) scan-
ning have been developed to improve the diagnostic rate of 
colorectal cancer. Improvements in treatment modalities 
such as surgery, radiation therapy, chemotherapy and tar-
geted therapies may also result in a lower death rate due to 
colorectal cancer. However, the outcomes of colorectal 
cancer diagnosed at advanced stages remain poor. The pro-
gress made in early diagnostic techniques and screening 
tests has been inadequate, and the majority of the molecular 
mechanisms of colorectal cancer are still unknown. Thus, 
there is an urgent requirement to characterize specific mo-
lecular changes that could identify patients with early can-
cer or precursor lesions. 
MicroRNAs (miRNAs) are small single-stranded RNA 
molecules of approximately 22 nucleotides (nt) long that 
regulate gene expression. They are naturally abundant and 
evolutionarily conserved non-coding RNA molecules found 
in both animals and plants. It is estimated that miRNAs reg-
ulate 10%–30% of all protein-coding genes by binding to 
partially complementary sequences in the 3′-untranslated 
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regions (3′UTR) of downstream target mRNAs [2,3]. 
MiRNAs mainly inhibit protein translation of their target 
genes and infrequently cause degradation or cleavage of 
mRNA. The first microRNA was identified in 1993 by Lee 
et al. [4]. Since then, various cloning and bioinformatics 
studies have predicted that the human genome may contain 
up to 1000 miRNAs. Growing evidence indicates that 
miRNAs are key regulators of a variety of fundamental bi-
ological processes such as cell proliferation, development, 
apoptosis, hematopoiesis, energy metabolism, neural de-
velopment, stress resistance, cell death and, importantly, 
tumorigenesis [5−8]. The expression data of miRNAs in 
various cancers demonstrated that cancer cells have differ-
ent miRNA profiles compared with normal cells. MiRNAs 
overexpressed in cancer may function as oncogenes or tu-
mor suppressors when downregulated in cancer. The initial 
evidence of the involvement of miRNAs in human cancer 
came from molecular studies in human chronic lymphocytic 
leukemia, which revealed two miRNAs, miR-16 and 
miR-15 [9]. More recently, miRNA dysregulation was de-
tected in other cancers [10−14], including gastric [15], 
prostate [16], lung [17], breast [18], ovarian [19] and hepa-
tocellular [20] cancer. These unique properties of miRNAs 
make them remarkably useful potential agents for clinical 
diagnostics as well as in future personalized care for indi-
vidual patients. 
In previous studies, we performed miRNA gene chip 
screening to detect the miRNA profiles of 25 colorectal 
cancer samples and 10 normal colorectal mucosa tissue 
samples. The results showed that in all colorectal cancer 
tissue compared with matched non-tumor tissue, 35 mi- 
RNAs were upregulated and 30 miRNAs were downregu-
lated. We observed that the expression levels of miR-142- 
3p were significantly increased and were associated with 
clinicopathological features [21]. Recent studies have re-
ported that miR-142-3p, which is located at chromosome 
17q22, is important in the tumorigenesis of human T-cell 
acute lymphoblastic leukemia (T-ALL) [22], hepatocellular 
carcinoma [23] and esophageal squamous cell carcinoma 
[24]. However, the function of miR-142-3p in colorectal 
cancer is largely unknown. 
In this study, we confirmed the miR-142-3p expression 
profile in human colorectal cancer tissues and several colo-
rectal cancer cell lines by quantitative real-time RT-PCR 
(qRT-PCR). Subsequent experiments predicted and identi-
fied the transcription factor 7 (T-cell specific, HMG box; 
TCF7) as a target of miR-142-3p, which was post-tran- 
scriptionally downregulated by miR-142-3p. Further study 
showed that overexpression of miR-142-3p could inhibit 
TCF7 functions in the control of cell proliferation in vitro. 
Therefore, we presumed that miR-142-3p may be involved 
in the regulation of cell proliferation in colorectal cancer. 
Our findings may help to enhance our understanding of the 
mechanisms of miRNAs in the tumorigenesis of colorectal 
cancer. 
1  Materials and methods 
1.1  Bacterial strain, plasmids, tissue samples and cell 
lines 
E. coli strain DH5 was preserved by the laboratory at our 
hospital. Gene expression vector GP/S/EGFP/B/CMV-miR 
plasmid and psiCHECK-2 dual-luciferase vector were pur-
chased from GenePharma (Shanghai, China). Colorectal 
cancer tissue and adjacent non-tumor tissue were collected 
from 60 patients who underwent colorectal cancer radical 
surgery at the Department of Oncosurgery at the Fourth 
Affiliated Hospital of Soochow University in 2010. All the 
patients did not receive preoperative treatment. TNM classi-
fication was defined according to the American Joint Com-
mittee on Cancer/Union for International Cancer Control 
(AJCC/UICC) (2010). The human colorectal cancer cell 
lines SW480, DLD-1, HCT116, HCT8 and human embryo 
colon mucosa cell line CCC-HIE-2 were maintained by the 
laboratory at our hospital. The cells were routinely cultured 
in RPMI-1640 supplemented with 10% fetal bovine serum 
and penicillin/streptomycin (100 U/mL) at 37°C in a hu-
midified atmosphere containing 5% (v/v) CO2. 
1.2  Bioinformatics analysis 
MiR-142-3p sequences were obtained in the microRNA 
authority database miRBase (http://www.mirbase.org/[25]). 
The miRNA target genes were predicted by miRanda 3.3a, 
RNAhybrid 2.1 and TargetSpy softwares, and the network 
resources of miRBase Targets (http://www.mirbase.org/), 
TargetScan (http://www.targetscan.org [26]) and PicTar 
(http://pictar.mdc-berlin.de/[27]). The KEGG pathway da-
tabase [28] and Expression Analysis Systematic Explorer 
(EASE) database were used to further analyze the overlap 
of these results. The 3′UTR of target genes were retrieved 
by UCSC human Gene Sorter (http://genome.ucsc.edu/cgi- 
bin/hgNear). 
1.3  Quantitative real-time PCR  
Total RNA was extracted from colorectal cancer cell lines, 
normal colorectal mucosal epithelial cell lines, cancer tissue 
and non-tumorous mucosal tissue using Trizol reagent 
(Invitrogen) according to the manufacturer’s instructions. 
The expression levels of miR-142-3p mRNA were exam-
ined using qRT-PCR according to the SYBR Real-Time 
PCR Kit protocol (GenePharma). Reverse transcription re-
actions were performed with MMLV Reverse Transcriptase 
(MBI) using the following reaction conditions: 26°C for 30 
min; 42°C for 30 min; and 85°C for 10 min. qRT-PCR was 
conducted on a real-time cycler (FTC2000) with the fol-
lowing cycling conditions: an initial step of 95°C for 3 min, 
followed by 40 cycles at 95°C for 30 s, 62°C for 20 s and 
72°C for 20 s. The threshold cycle (Ct) values were ana-
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lyzed using the comparative Ct method. The amount of tar-
get was obtained by normalizing to the endogenous refer-
ence (U6). Each experiment was repeated three times. 
1.4  Construction of miR-142-3p-expression plasmid 
and miR-142-3p-Silencer plasmid 
The DNA sequence of miR-142-3p was amplified from 
cDNA isolated from SW480 cells and cloned into the Bbs I 
and BamH I sites of the GP/S/EGFP/B/CMV-miR plasmid 
(GenePharma) with the following sequence: hsa-miRAN- 
142-S: 5′-TGCTGTGTAGTGTTTCCTACTTTATGGAG- 
TTTTGGCCACTGACTGACTCCATAAAAGGAAACAC
TACA-3′, hsa-miRAN-142-A: 5′-CCTGTGTAGTGTTTC- 
CTTTTATGGAGTCAGTCAGTGGCCAAAACTCCATA- 
AAGTAGGAAACACTACAC-3′. MiR-142-3p Silencer 
plasmid was constructed with the following sequences: 
hsa-miRAN-142-S: 5′-TGCTGTCCATAAAGTAGGAAA- 
CACTACAGTTTTGGCCACTGACTGACTCCATAAAA- 
GGAAACACTACA-3′, hsa-miRAN-142-A: 5′-CCTGTCC-  
ATAAAGTAGGAAACACTACAGTCAGTCAGTGGCCA
AAACTCCATAAAGTAGGAAACACTACAC-3′. Finally, 
the constructs were verified by sequencing and named pPG/ 
miR/eGFP/Blasticidin-miR-142-3p and pPG/miR/eGFP/ 
Blasticidin-miR-142-3p-Silencer, respectively. 
1.5  Construction of dual-luciferase vector comprising 
the TCF7 3′UTR  
The 3′UTR segment of TCF7 was amplified from SW480 
cDNA using the following primers: 5′-TTCCTCGAGGCTG- 
CCCCGGGTCCCCA-3′ (forward) and 5′-TGCGCGGCCG- 
CTCAGGCTTTGAAAAACAAACCC-3′ (reverse). The 
mutant TCF7 3′UTR segment was obtained by two rounds 
of PCR. The first round of PCR was performed using the 
following combination of primers: 5′-TTCCTCGAGGCT- 
GCCCCGGGTCCCCA-3′ (forward) and 5′-TTGCCTGAT- 
AAGGCAGATTATTTCTG-3′ (reverse); and 5′-CAGAA- 
ATAATCTGCTTATCAGGCAA-3' (forward) and 5′-TGC- 
GCGGCCGCTCAGGCTTTGAAAAACAAACCC-3′ (re-
verse). The two mutant PCR products were ligated and a 
second round of PCR was performed with the following 
primers: 5′-TTCCTCGAGGCTGCCCCGGGTCCCCA-3′ 
(forward) and 5′-TGCGCGGCCGCTCAGGCTTTGAAA- 
AACAAACCC-3′ (reverse). Finally, the segments of wild- 
type and mutant TCF7 3′UTRs were cloned upstream of the 
firefly luciferase gene into the psiCHECK-2 vector 
(Promega). Both constructs were verified by sequencing and 
named psiCHECK-2/TCF7 and psiCHECK™-2/TCF7/mut, 
respectively. 
1.6  Transient transfection of miR-142-3p and miR- 
142-3p-Silencer plasmid 
The miR-142-3p and miR-142-3p-Silencer plasmids were 
constructed as above. The negative control (NC) RNA du-
plex with a sequence of S: 5′-TGCTGAAATGTACTGCG- 
CGTGGAGACGTTTTGGCCACTGACTGACGTCTCCA- 
CGCAGTACATTT-3′, A: 5′-CCTGAAATGTACTGCGT- 
GGAGACGTCAGTCAGTGGCCAAAACGTCTCCACGC
GCAGTACATTTC-3′ was nonhomologous to any human 
genome sequences, and was purchased from GenePharma.  
SW480 cells were cultured in 24-well plates the day be-
fore transfection to ensure 60%–70% cell confluence at 
transfection. Plasmids were extracted, quantified, and 
transfected into SW480 cells with Lipofectamine 2000 rea-
gent (Invitrogen) according to the manufacturer’s instruc-
tions. A final concentration of 500 nmol/L miR-142-3p, 
miR-142-3p inhibitor or negative control was used for each 
transfection. Moreover, for each transfection, a blank con-
trol without plasmid was prepared. The cells were analyzed 
48 h after transfection in proliferation assay and target gene 
experiments. Each experiment included three parallel 
groups, and the above experiment was performed in tripli-
cate in each parallel group. 
1.7  Dual-luciferase assay 
Dual-luciferase assays were performed according to the 
Dual-Luciferase Reporter Assay System Technical Manual 
(Promega). SW480 cells were plated at 5×104 cells per well 
in 24-well dishes and co-transfected with Lipofectamine 
2000 (Invitrogen) 36 h later according to the manufacturer’s 
recommendations. Each co-transfection reaction contained 
500 ng of either psiCHECK-2/TCF7 or psiCHECK-2/TCF7/ 
mut and various concentrations of miR-142-3p plasmid. An 
additional miRNA with no predicting binding site in the 
TCF7 3′UTR was used as a control. The relative luciferase 
activity (firefly luminescence/Renilla luminescence) of the 
transfected cells in each group was determined with the 
Thermo Scientific Fluoroskan Ascent FL, and used to rep-
resent the transcriptional activity of the TCF7 3′UTR by 
miR-142-3p. 
1.8  Western blot analysis 
Western blotting was performed to detect the relative levels 
of TCF7 protein after transfection with miR-142-3p-   
expression plasmid, miR-142-3p-Silencer plasmid or miR- 
142-3p-NC plasmid, and TCF7 protein in four colorectal 
cancer cell lines and one normal colorectal mucosal epithe-
lial cell line. Total proteins of all cell lines were extracted 
and quantified by the Bradford method [16]. Proteins were 
boiled and loaded onto 10% SDS polyacrylamide gels and 
electrophoretically transferred onto PVDF membranes. 
Then, membranes were blocked in 5% non-fat milk in TBS 
with 0.05% Tween-20 (TBST) at room temperature for 1 h 
and stained with TCF7 monoclonal antibody (1:200, Epi-
tomics) and GAPDH antibody (Abcam). Protein was visu-
alized using the BM Chemiluminescence Western Blotting 
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Kit according to the manufacturer’s instructions. 
1.9  RT-PCR 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
was performed to detect the relative transcript levels of 
TCF7 mRNA after transfection with miR-142-3p-expres- 
sion plasmid, miR-142-3p-Silencer plasmid or miR-142-3p- 
NC plasmid, its mRNA expression levels in several colo-
rectal cancer cell lines and colorectal cancer tissues. The 
cDNA was generated using the methods mentioned above. 
TCF7 and GADPH were amplified using the following pri-
mers: TCF7: 5′-GCTGGTTCACCCACCCATCCTT-3′ 
(forward) and 5′-GCCTCTTCTTCTTCCCGTAGTTGTC-3′ 
(reverse); GADPH, 5′-TGAACGGGAAGCTCACTGG-3′ 
(forward) and 5′-TCCACCACCCTGTTGCTGTA-3′ (re-
verse), generating PCR product sizes of 413 and 307 bp 
respectively, with the following PCR conditions: 94°C for 5 
min followed by 30 cycles of 94°C for 45 s, 56°C for 45 s 
and 72°C for 1 min. The expression of GAPDH was ana-
lyzed as a control. All primers were purchased from Sangon 
Biotech Co., Ltd. (Shanghai, China). 
1.10  Cell proliferation assays 
Cell proliferation was measured with a cholecystokinin- 
octopeptide (CCK-8) assay. Twenty-four hours after trans-
fection with miR-142-3p, miR-142-3p-inhibitor or NC, cells 
(approximately 1×103) were seeded into 96-well dishes for 
12, 24, 36, 48, 60 and 72 h. The cells were then incubated 
with 10 μL CCK-8 for 1 h at 37°C. The optical density was 
determined with a spectrophotometer at a wavelength of 
450 nm. Growth curves were plotted according to the ODs. 
1.11  Immunohistochemistry assays 
Immunohistochemical analysis was performed to detect 
TCF7 protein expression in human colorectal cancer tissues 
compared with normal colorectal mucosa tissues. Paraffin- 
embedded and formalin-fixed samples were cut into 4-μm 
sections, which were then processed for immunohistochem-
ical examination. Histopathological diagnosis for tumor 
tissues and non-tumor tissues was performed using estab-
lished criteria. After deparaffinization and rehydration, the 
sections were boiled in 10 mmol/L of citrate buffer (pH 6.0) 
for 10 min for antigen retrieval. Then endogenous peroxi-
dase activity was inhibited for 30 min with methanol con-
taining 3% H2O2, followed by incubation with normal 
non-immune goat sera for 30 min. Subsequently, sections 
were incubated with mouse anti-human TCF7 monoclonal 
antibody (1:200, Epitomics) overnight at 4°C. The immune 
complex was visualized with the Dako REAL EnVision 
Detection System Peroxidase/DAB Rabbit/Mouse (Dako). 
Negative controls were run by replacing the primary anti-
body with PBS or normal mouse IgG1. The results of TCF7 
protein staining were categorized as either negative or posi-
tive based on the presence of clear brown color staining in 
the cytoplasm and cell membrane. Specimens with more 
than 10% positive cells were graded as positive. 
1.12  Statistical analysis 
The data from each group were calculated and presented as 
mean±SD from at least three separate experiments. Statisti-
cal analysis was carried out using SPSS 13.0 computer 
software, and non-parametric test and two-tailed Student’s 
t-test were performed to compare groups. P<0.05 indicates a 
statistically significant difference. 
2  Results 
2.1  Upregulated miR-142-3p expression in colorectal 
cancer tissues and colorectal cancer cell lines correlates 
with the degree of tumor differentiation 
MiR-142-3p was detected in all 60 (100%) pairs of colorec-
tal cancer tissues, their matched non-tumor adjacent tissues, 
their normal colorectal mucosal tissues and three colorectal 
cancer cell lines using qRT-PCR. Our results confirmed that 
the average expression level of miR-142-3p was signifi-
cantly upregulated in tumor tissue compared with matched 
non-tumor adjacent tissue (3.81±1.62 vs. 1.43±0.57; P<0.05) 
(Figure 1(a)). The expression level of miR-142-3p was also 
significantly upregulated in these colorectal cancer cell lines 
compared with a normal colorectal mucosal epithelial cell 
line and normal colorectal mucosal tissue (Figure 1(b)). The 
results are consistent with our previous miRNA microarray 
results.  
Then, we analyzed the relationship between miR-142-3p 
and clinicopathological characteristics of colorectal cancer. 
The Mann-Whitney U test revealed that the expression level 
of miR-142-3p was associated with the degree of tumor 
differentiation (P=0.002) in colorectal cancer. The patients 
tended to have poorly differentiated cancer tissues with high 
miR-142-3p expression. However, the miR-142-3p expres-
sion level had no correlation with tumor site, gender, age, 
histological type, deeper local invasion, lymph node metas-
tasis and TNM stage. 
2.2  TCF7 is a target of miR-142-3p 
Because miR-142-3p has an overexpression profile in colo-
rectal cancer, we studied how this miRNA exerts its func-
tion in colorectal cancer. We predicted its potential target 
genes using miRanda 3.3a, RNAhybrid 2.1 and TargetSpy 
and the TargetScan, miRBase, PicTar algorithms. The genes 
predicted by all the algorithms were chosen as the candidate 
target genes of miR-142-3p. Among them, TCF7 was found 
to have a putative miR-142-3p binding site within its 3′UTR. 
TCF7 is a member of the HMG box transcription factor  
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Figure 1  MiR-142-3p expression in colorectal cancer tissues and colo-
rectal cell lines. MiR-142-3p was detected in 60 colorectal cancer samples, 
three colorectal cancer cell lines, a human embryo colon mucosa cell line 
and the corresponding normal colorectal mucosal tissues by qRT-PCR. (a) 
The relative expression level of miR-142-3p in colorectal cancer tissue, 
their matched non-tumor adjacent tissue and normal colorectal mucosal 
tissue. (b) The relative expression level of miR-142-3p in three colorectal 
cancer cell lines, a human embryo colon mucosa cell line and normal colo-
rectal mucosal tissue. The mean and standard deviation of miR-142-3p 
expression levels are shown. The data represent triplicate measurements 
from single RNA samples (P<0.05). 
family that plays a key role in the signaling pathways (Fig-
ure 2) regulating cell proliferation and adhesion (Table 1). 
Our subsequent experiments confirmed TCF7 was an au-
thentic target gene of miR-142-3p in colorectal cancer. In 
our experiments, the region of the TCF7 3′UTR mRNA was 
cloned downstream of the firefly luciferase gene in the 
psiCHECK-2 dual-luciferase vector to construct the reporter 
vector psiCHECK-2-TCF7-3′UTR. Then, it was co-trans- 
fected into SW480 cells with miR-142- 3p precursor or 
control precursor. The repression of firefly luciferase activ-
ity was observed in SW480 cells co-transfected with 
psiCHECK-2-TCF7-3′UTR and miR-142-3p precursor, but 
not in SW480 cells co-transfected with psiCHECK-2-TCF7- 
3′UTR and control precursor (Figure 3). To elucidate 
whether miR-142-3p interacted with a specific target se-
quence localized in the 3′UTR of TCF7, we constructed 
another reporter vector, psiCHECK-2/TCF7/mut, in which 
the 7-bp “seed” sequence (UGUGAUG) was deleted using 
PCR. It was co-transfected into SW480 cells with miR-142- 
3p precursor or control precursor, and the dual-luciferase 
activity was measured. It was noteworthy that miR-142-3p 
could no longer decrease the firefly luciferase activity of 
psiCHECK-2/TCF7/mut (P<0.05) (Figure 3(b)). In conclu-
sion, TCF7 3′UTR carries direct binding sites for miR-142- 
3p. 
2.3  MiR-142-3p could inhibit TCF7 expression in a 
dose-dependent manner 
According to the experimental results in the above section, 
the regulatory effect of different doses of miR-142-3p on 
TCF7 3′UTR was analyzed. We observed that the higher the 
dose of miR-142-3p, the lower the relative activity of the 
luciferase. The results demonstrated that the inhibition of 
TCF7 by miR-142-3p was dose-dependent (Figure 4). 
2.4  MiR-142-3p post-transcriptionally downregulates 
TCF7 expression 
MiRNAs regulate 10%–30% of all protein-coding genes by 
binding to partially complementary sequences in the 3′UTR 
of downstream target mRNAs. miRNAs mainly inhibit pro-
tein translation of their target genes and infrequently cause 
degradation or cleavage of the mRNA. We performed RT- 
PCR and Western blot assays to verify how miR-142-3p 
regulates TCF7. As shown in Figure 5(a), RT-PCR analysis 
of TCF7 showed that miR-142-3p had no effect on TCF7 
mRNA levels. Nevertheless, TCF7 protein levels were de-
creased in miR-142-3p-transfected SW480 cells but in-
creased in miR-142-3p-Silencer-transfected SW480 cells 
compared with NC-transfected SW480 cells (Figure 5(b)). 
These results demonstrate that miR-142-3p negatively reg-
ulates TCF7 expression post-transcriptionally. 
2.5  MiR-142-3p inhibits cell proliferation in vitro 
The significant upregulation of miR-142-3p expression in 
colorectal cancer samples prompted investigation of the 
possible biological roles of miR-142-3p in tumorigenesis. 
First, we detected miR-142-3p expression by qRT-PCR  
48 h after transfection of miR-142-3p, miR-142-3p-Silencer, 
their NC and blank controls. Transfection efficiency was 
satisfactory. The results of the CCK8 assays and growth 
curves indicated that proliferation was inhibited at different 
degrees in the SW480 cells transiently transfected with 
miR-142-3p (P<0.05), while those cells transfected with 
miR-142-3p-Silencer had significant growth promotion 
compared with that of the cells transfected with NC and 
blank controls (P<0.05). No statistically significant differ-
ence was observed between NC and blank controls (P>0.05) 
(Figure 6). 
2.6  TCF7 mRNA and protein expression was upregu-
lated in four colorectal cancer cell lines  
Using RT-PCR, TCF7 mRNA was detected in four colorectal 
cancer cell lines and a human embryo colon mucosa cell 
line. Results showed that the average expression level of 
TCF7 mRNA was significantly upregulated in colorectal 
cancer cells compared with normal colorectal mucosal cells 
(P<0.05) (Figure 7).  
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Figure 2  The TCF7 pathway in colorectal cancer. 
Table 1  Target gene prediction for miR-142-3p 
Signaling pathway Gene Ensembl gene ID 
Cell cycle_Initiation of mitosis 
CDC25C ENSG00000158402 
MNAT1 ENSG00000020426 
Development_WNT signaling pathway. Part 2 
TCF7 ENSG00000081059 
FZD7 ENSG00000155760 
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 
TCF7 ENSG00000081059 
FZD7 ENSG00000155760 
Cell adhesion_Role of CDK5 in cell adhesion TCF7 ENSG00000081059 
Transport_RAB3 regulation pathway DMXL2 ENSG00000104093 
 
 
Western blot assays were performed to detect TCF7 pro-
tein in four colorectal cancer cell lines and human embryo 
colon mucosa cell line. As shown in Figure 8, TCF7 protein 
levels were significantly higher in colorectal cancer cell 
lines than in human embryo colon mucosa cells (P<0.05). 
2.7  TCF7 mRNA and protein expression in human 
colorectal cancer tissues 
TCF7 mRNA was detected in human colorectal cancer tis-
sues and the corresponding normal colorectal mucosal tis-
sues with RT-PCR. Results showed that the average expres-
sion levels of TCF7 mRNA were significantly upregulated 
in colorectal cancer tissues compared with the correspond-
ing controls (P<0.05) (Figure 9).  
Tissue immunochemistry was carried out with a TCF7 
monoclonal antibody to detect TCF7 protein in human col-
orectal cancer tissues. As shown in Figure 10, TCF7 ex-
pression was +++ in the colorectal cancer tissues, ++ in 
their matched non-tumor adjacent tissue, while in normal  
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Figure 3  TCF7 is a validated target of miR-142-3p. (a) Putative binding 
sites of miR-142-3p in the TCF7 3′UTR (ACACUAC). (b) miR-143-3p 
decreased luciferase activity controlled by wild-type TCF7 3′UTR 
(P<0.05) but did not affect luciferase activity controlled by mutant TCF7 
3′UTR (ACACUAC). 
 
Figure 4  Dose-dependent regulation of TCF7 3′UTR by miR-142-3p. 
The results demonstrated that miR-142-3p could inhibit TCF7 expression 
in a dose-dependent manner (the dose of miR-142-3p in each group from 1 
to 6 was 500, 400, 300, 200, 100, and 0 ng, respectively). 
colorectal tissue it was +.  
3  Discussion 
In contrast to their tight regulation during development and 
in normal tissues, miRNAs are abnormally expressed in 
cancer. MiRNAs that are overexpressed in cancer may 
function as oncogenes, and may function as tumor suppres-
sors when downregulated in cancer. Thus, they are regarded 
as important modulators in a variety of fundamental cellular 
biological processes, and appear to play a pivotal role in 
human carcinogenesis. For instance, it was reported that 
high expression levels of miR-21 were significantly corre-
lated with lymph node metastasis, advanced clinical stage, 
and poor prognosis in patients with breast cancer [29]. 
MiR-142-3p was recently identified as an oncogenic mi- 
RNA in human T-cell acute lymphoblastic leukemia  
 
Figure 5  MiR-142-3p post-transcriptionally downregulates TCF7 ex-
pression. (a), (b) TCF7 mRNA in SW480 cells was detected by RT-PCR at 
48 h post-transfection with miR-142-3p, miR-142-3p-Silencer, NC and 
blank controls (mock). The results are shown as fold changes relative to the 
control cells. (c), (d) TCF7 protein in SW480 cells was analyzed by west-
ern blot at 48 h post-transfection with miR-142-3p, miR-142-3p-Silencer, 
their respective NCs and blank controls (mock). The expression of 
GAPDH was analyzed as a control. 
 
Figure 6  Growth curves of each group as measured by CCK-8 assay. 
Proliferation was inhibited in SW480 cells transfected with miR-142-3p, 
and cells transfected with miR-142-3p-Silencer had a significant growth 
promotion compared with cells transfected with NC and blank controls 
(mock). All results were reproducible in three independent experiments 
(P<0.05). 
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Figure 7  TCF7 mRNA expression in four colorectal cancer cell lines and 
human embryo colon mucosa cell lines. (a) TCF7 mRNA expression in 
SW480, DLD-1, HCT116, HCT8 human colorectal cell lines and CCC- 
HIE-2 human embryo colon mucosa cells as demonstrated by RT-PCR.  
(b) The fold changes in TCF7 mRNA in these cell lines. The mean and 
standard deviation of TCF7 mRNA expression levels are shown.  
 
Figure 8  Western blot assays of TCF7 protein in four human colorectal 
cell lines and human embryo colon mucosa cells. (a) TCF7 protein expres-
sion in SW480, DLD-1, HCT116, HCT8 human colorectal cell lines and 
CCC-HIE-2 human embryo colon mucosa cells. (b) The fold changes of 
TCF7 protein in these cell lines. The mean and standard deviation of TCF7 
mRNA expression levels are shown. 
(T-ALL) by targeting the glucocorticoid receptor-a and the 
cAMP/PKA pathways [22]. Wu et al. [23] demonstrated 
that miR-142-3p directly and negatively regulates RAC1 in 
HCC cells, and suppresses the migration and invasion of 
hepatocellular carcinoma cells. Another study reported that 
miR-142-3p was a potential prognostic biomarker for 
esophageal squamous cell carcinoma [24]. However, the 
potential function of miR-142-3p in colorectal cancer was 
not determined. In previous studies, we performed miRNA 
gene chip screening to detect miRNA profiles in colorectal 
cancer tissues. We observed that the expression level of 
miR-142-3p was significantly upregulated and was associated  
 
Figure 9  TCF7 mRNA expression in colorectal cancer tissues. (a) TCF7 
mRNA in colorectal cancer tissues demonstrated by RT-PCR. (b) The fold 
changes of TCF7 mRNA in colorectal tissues, non-tumor adjacent tissues 
and normal mucosal tissues. The mean and standard deviation of TCF7 
mRNA expression levels are shown. 
with clinicopathological features; therefore, we focused on 
miR- 142-3p for further study.  
It is clear that the fundamental function of miRNAs is to 
regulate protein-coding genes. This occurs via two mecha-
nisms: first, miRNAs induce the RNA-mediated interfer-
ence (RNAi) pathway by binding to protein-coding mRNA 
sequences [30] that are exactly complementary to the 
miRNA, leading to cleavage of mRNA. Second, miRNAs 
bind to imperfect complementary sites within the 3′UTRs of 
their target protein-coding mRNAs, leading to repression of 
the expression of these genes at the translational level. In 
humans, miRNAs mainly inhibit protein translation of their 
target genes and infrequently cause degradation or cleavage 
of the mRNA. Nowadays, we use computational algorithms 
to predict miRNA targets, which are based mainly on base 
pairing of miRNAs and target gene 3′UTRs [31]. In our 
study, we predicted the potential target genes of miR-142- 
3p by using miRanda 3.3a, RNAhybrid 2.1 and TargetSpy 
and the TargetScan, miRBase, PicTar algorithms. The genes 
predicted by all the algorithms were chosen as the candidate 
target genes of miR-142-3p. Among them, TCF7 was found 
to have a putative miR-142-3p binding site within its 3′UTR. 
Further studies provided further evidence to confirm our 
prediction. First, the repression of firefly luciferase activity 
was observed in SW480 cells co-transfected with 
psiCHECK-2-TCF7-3′UTR and miR-142-3p precursor, but 
not in SW480 cells co-transfected with psiCHECK-2-TCF7- 
3′UTR and control precursor. Second, miR-142-3p could 
not decrease the firefly luciferase activity of psiCHECK- 
2/TCF7/mut. Third, overexpression of miR-142-3p post- 
transcriptionally downregulates TCF7 protein expression.  
TCF7 is a member of the HMG box transcription factor 
family, which also includes TCF-4, a locus implicated in 
some colorectal cancers. The TCF7 gene product is a tran-
scription factor that affects the expression of genes critical 
to Th1 responses, such as the interleukin (IL)-12R subunit, 
which is important in cell-mediated immunity. TCF7  
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Figure 10  Immunohistochemical analysis of TCF7 protein in human colorectal cancer tissue, adjacent tissue and normal tissue. (a) and (d) human colorec-
tal adenocarcinoma tissue; (b) and (e) adjacent colorectal tissue; (c) and (f) normal human colorectal tissue. Magnifications are 40 (a), (b), (c), 200 (d), (e), 
(f); slice thickness is 4 μm. 
expression is limited to T- and NK-cells. Knockout experi-
ments in mice have shown that TCF7 is necessary for T-cell 
development in the thymus. The latest findings showed 
TCF7 protein has crucial functions in signaling pathways 
such as the Wnt pathway and other pathways involved in 
regulating cell adhesion, cytoskeleton reorganization, pro-
liferation, apoptosis and migration [32−34]. Accumulating 
research indicated TCF7 may function as an oncogene. The 
expression of TCF7 is upregulated in many cancers, includ-
ing colorectal, endometrial, and prostate cancer, and may be 
correlated with poor prognosis. All this evidence shows that 
TCF7 plays a key role in cancer pathogenesis. 
In this study, we confirmed significant upregulation of 
miR-142-3p in colorectal cancer tissues and colorectal can-
cer cell lines. We predicted and identified TCF7 as a target 
of miR-142-3p. Furthermore we found miR-142-3p nega-
tively regulates TCF7 expression post-transcriptionally, and 
overexpression of miR-142-3p in SW480 colorectal cancer 
cell lines potently inhibited cell proliferation in vitro by 
inhibiting the expression level of TCF7. TCF7 mRNA and 
protein expression is upregulated in colorectal cancer tis-
sues and several colorectal cancer cell lines, and is closely 
correlated with its function as an oncogene in promoting 
tumor cell proliferation and inhibiting cell apoptosis, which 
are known malignant characteristics of tumors. Our results 
suggested that miR-142-3p may be involved in the regula-
tion of cell proliferation in colorectal cancer, with TCF7 as 
a direct target. As each gene is regulated by a variety of 
regulatory factors, we presumed that there must be other 
pathways that upregulate the levels of TCF7 in colorectal 
cancer. The upregulation of miR-142-3p could not inhibit 
TCF7, highlighting the complicated systems operative in 
tumorigenesis.  
Recent research has enabled the identification of hun-
dreds of human miRNAs, but most of their targets remain 
unknown and we still know little about their mechanisms of 
action and the pathways they modulate. In our study, the 
identification of miR-142-3p and its target gene, TCF7, in 
colorectal cancer may help in understanding the potential 
molecular mechanisms of colorectal cancer development 
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